Press Release
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
|
Liver Line is envisioned as a central gathering place for patients, medical professionals and researchers to learn about the latest research in liver health and the treatment of diseases such as non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis. Liver Line will also discuss how the mechanisms behind liver disease are connected to other diseases.
"Liver health should be as important to everyone as heart health," said Dr. Peter Traber, President, Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics. "Just as with the heart, you only have one liver. Everything you eat passes through your liver on its way from the digestive tract to the rest of the body. However, while we know how to live a heart-healthy life, most people know nothing about how to ensure a healthy liver."
Liver diseases such as fatty liver disease, NASH, and cirrhosis are often called a "hidden epidemic." By some estimates, up to a quarter of the people in world are affected by fatty liver disease, with a lifetime risk of some 20 million people dying as a result. Yet, few people talk about liver health and there are no approved therapies for NASH fibrosis or NASH cirrhosis. Liver Line looks to make these issues and this research more visible.
"We have only one liver, and it's so important that it has a tremendous reserve capacity," continued
The Liver Line is sponsored by
About
Contacts:Jack Callicutt , Chief Financial Officer (678) 620-3186 ir@galectintherapeutics.com
Source:
News Provided by Acquire Media